GUTS

BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the third quarter 2026 and provide business updates on Thursday, November 12, 2026, at 4:30 p.m. ET.

BURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced additions to its U.S. patent portfolio that strengthen the intellectual property foundation for investigational Revita® as the Company advances toward a planned U.S. Food and Drug Administration (FDA) De Novo marketing submission for post-GLP-1 weight maintenance.

Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication A one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Fractyl Health, Inc. (NASDAQ: GUTS) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 19, 2026 /PRNewswire/ -- What is the Investigation About? On January 29, 2026, before the market opened, Fractyl Health, Inc. announced six-month data from its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after discontinuation of GLP-1 therapy.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (""Fractyl" or the "Company") (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts

New class action for Fractyl (GUTS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/20/2026

Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading days. Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading days.

Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance Transcript